• Harrow Health Inc (NASDAQ: HROW) entered a binding agreement to acquire the exclusive U.S. commercial rights to five FDA‑approved ophthalmic products from Novartis AG (NYSE: NVS).

• This acquisition will further expand and diversify Harrow's portfolio of branded pharmaceutical products and its ability to serve the U.S. ophthalmic surgical and acute care markets.

• Assuming this transaction closes during Q1 of 2023, Harrow expects 2023 net revenues of $135-$143 million and adjusted EBITDA of $44-$50 million.

• Harrow will make a one-time payment of $130 million, with up to an additional $45 million payable in a milestone payment upon the commercial availability of TRIESENCE, which is expected in 2H of 2023.

• Novartis will retain all rights to the products outside of the U.S.

• Harrow commenced an underwritten registered public offering of $100 million aggregate principal amount of senior notes due 2027 to fund a portion of the purchase price payable for a previously announced acquisition.

• The company also priced an underwritten registered offering of 2.37 million shares at $10.52 for aggregate gross proceeds of $25 million.

• Price Action: HROW shares are up 6.31% at $11.80 on the last check Wednesday.

See more from Benzinga

• AbbVie, Ipsen Terminate Partnerships With Exicure As Bankruptcy Concern Looms

• Icosavax Highlights Six Months Durability Data For Respiratory Syncytial Virus Vaccine Candidate

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.